NewHold Investment IV

This advances the registration-to-pricing timeline, indicating preparation to collect capital ahead of any subsequent combination search or extension considerations. It does not alter the April 16, 2028 redemption deadline, the $10.06 per share trust account balance, or any existing deal progress or sponsor conduct parameters you track. Aside from routine administrative routing to legal counsel Loeb & Loeb LLP, the filing discloses no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All procedural assertions and the acceleration request originate solely from BTIG, LLC’s authorized signatory and the registrant’s filing team.

This is the governing disclosure document for NHIV's proposed IPO and will set the trust-per-share value, redemption procedures, liquidation deadline, sponsor economics, dilution and investor protections from the moment the SPAC lists. It gives existing and prospective investors the mechanics they need to track redemption terms and the start of the 24-month completion window, and it confirms there is no pending business combination, extension vote or redemption event today. It is also the source for sponsor-conduct concerns: nominal-price founder shares, deferred success-only compensation, broad discretion to amend the sponsor letter agreement, anti-dilution founder-share conversion, and the sponsor's ability to make permitted purchases of public shares.

Establishes the terms of a new SPAC IPO with a $175 million trust ($10.00 per share), a 24-month deadline (extendable by shareholder vote), and standard redemption rights. The sponsor purchased founder shares at a nominal price, creating a conflict of interest. The filing details the sponsor's compensation and lock-up arrangements. There is no target business identified yet.

This filing establishes all initial terms for a new SPAC by the NewHold group. While it initiates no redemption deadline or deal risk (the SPAC is pre-IPO), it is material for investors tracking sponsor conduct and terms. The filing discloses an unusually high degree of potential conflicts: the management team's roles at NHIC I (Evolv), the liquidated NHIC II, and the still-searching NHIC III create a 'queue' of potential targets. The non-managing sponsor investors' expression of interest in purchasing substantially all of the offering, combined with their indirect founder-share stake, raises governance concerns about a controlled company. The 24-month deadline (extendable with shareholder vote) and the $10.06 trust value are standard but set the baseline for all future monitoring.

This filing establishes the baseline terms for NHIV's IPO. Investors can track trust value of $10.06 vs. the $10.00 deposit; note the 24-month deadline (approx. April 2028); the sponsor's nominal cost creating dilution risk; and the explicit statement that no target has been selected. The filing also details redemption mechanics, extension provisions, and conflict-of-interest disclosures that investors should monitor.

What changed: A routine compliance exhibit—specifically, a Joint Filing Agreement attached to a Schedule 13G beneficial ownership report, executed pursuant to Rule 13d-1(k). Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct, this filing introduces no changes. It contains no language modifying the redemption window, the per-share trust balance, any proposed business combination timeline, extension voting mechanics, or sponsor governance standards. The only operational update is administrative: it formalizes that Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross will submit future Schedule 13G amendments jointly, with each party bearing independent responsibility for the completeness and accuracy of their own disclosures, and liability for third-party inaccuracies limited to instances where they know or have reason to believe the information is false. The agreement is dated August 12, 2026. Why it matters: No substantive business, financial, or strategic claims appear in this document. There are no statements regarding customers, revenue streams, market sizing, investment strategy, proprietary technology, commercial partnerships, litigation exposure, or personnel movements. Because no executives, sponsors, or target company representatives are cited, and because the text exclusively governs SEC reporting logistics among affiliated holders, there are no attributable forward-looking assertions or operational disclosures. Consequently, this filing does not alter NHIV’s search-phase trajectory, trust preservation obligations, or de-SPAC structural timeline. Investors monitoring the redemption calendar, extension thresholds, or sponsor alignment should treat this as a procedural administrative record with zero economic or mechanical impact on the SPAC vehicle.

What changed: A Form 8-K current report documenting the resignation of Chief Financial Officer Polly Schneck and the Board's simultaneous appointment of John Boone as her successor. On July 22, 2026, Polly Schneck gave written notice of her resignation as CFO, effective immediately, stating per the filing that she departs to pursue other professional opportunities and that the Board confirmed no disagreements with management or corporate policy. The Board immediately appointed John Boone as CFO effective the same date. Kevin Charlton continues serving as Chief Executive Officer. The filing discloses that Mr. Boone's compensation arrangements have not yet been finalized and will be reported when determined. Why it matters: The executive transition shifts financial leadership during the SPAC’s search window (deadline 2028-04-16). The Board’s swift appointment of a replacement with documented experience across public equity, private equity, and restructuring investment banking signals an orderly handover rather than operational distress. However, the unfinalized compensation package for Mr. Boone leaves potential executive expense variables open until disclosed. Redemption mechanics remain untouched: the trust maintains $10.06 per share, no extension has been proposed, and no business combination or target engagement is referenced in this filing.

What changed: Amendment No. 1 to NewHold Investment Corp IV's Form 10-Q for the quarter ended March 31, 2026, filed July 21, 2026 and stated to be solely to correct typographical errors. The pre-IPO shell reported total assets of $281,000, total current liabilities of $341,000, accumulated deficit widening from $47,000 to $85,000, and $86,000 drawn against a sponsor promissory note capped at $350,000. Note 8 discloses the April 16, 2026 IPO of 20,125,000 units at $10.00 with the over-allotment exercised in full, and $201,250,000 placed in trust with Continental Stock Transfer & Trust. Why it matters: The Liquidity note still carries a stray drafting comment mid-sentence - 'should document that subsequent to 3/31 the IPO alleviated substantial doubt' - inside an amendment whose only stated purpose was fixing typographical errors, so the cleanup was incomplete. Substantively the figures that matter are post-quarter: $201,250,000 in trust against 20,125,000 public shares is $10.00 per share, and $7,043,750 of deferred underwriting discount sits ahead of shareholders at any closing. Sponsor and BTIG bought 641,250 private placement units at $10.00.

What changed: Quarterly report on Form 10-Q for the period ended March 31, 2026, filed by blank check company NewHold Investment Corp IV. The 10-Q covers the pre-IPO quarter ended March 31, 2026. Key subsequent event: On April 16, 2026, NHIV consummated its IPO of 20,125,000 units at $10.00/unit (including full exercise of the over-allotment option), generating gross proceeds of $201,250,000. Simultaneously, it completed a private placement of 641,250 units to the Sponsor and BTIG, LLC at $10.00/unit. Total of $201,250,000 was placed into trust ($10.00 per public share). The trust was funded as of April 16, 2026. At March 31, 2026, the company had no cash, deferred offering costs of $277,000, and an accumulated deficit of $85,000. It reported a net loss of $38,000 for the quarter. No Class A shares were outstanding at period end; only 6,708,333 Class B founder shares were outstanding (up to 875,000 subject to forfeiture). The underwriters' deferred discount is $7,043,750. The completion window is 24 months from the IPO close (i.e., by April 16, 2028). Why it matters: This filing confirms the SPAC is fully funded post-quarter, with $201.25M in trust ($10.06 per share, including deferred underwriting commissions). The deadline to complete a business combination is April 16, 2028. No target has been identified or discussions initiated as of the filing date; the company is in the active search phase. The filing establishes the baseline trust value, unit structure (one share plus 1/3 warrant), warrant exercise price of $11.50, and standard sponsor lock-up and redemption mechanics.

What changed: A Form 8-K current report and attached audited balance sheet announcing the consummation of NewHold Investment Corp IV’s initial public offering. The registrant reports that its IPO closed on April 16, 2026, selling 20,125,000 units at $10.00 per unit, generating $201,250,000 in gross proceeds. The filing confirms that $201,250,000 was placed in a U.S.-based trust account with Continental Stock Transfer & Trust Company acting as trustee. The company’s amended and restated memorandum and articles establish a 24-month Completion Window from the April 16, 2026 closing, meaning redemption or liquidation if no business combination occurs by April 16, 2028. The filing details a simultaneous private placement of 641,250 units to Sponsor NewHold Industrial Technology IV LLC and underwriter BTIG, LLC at $10.00 per unit. Deferred underwriting commissions of $7,043,750 are payable only upon business combination completion. The Sponsor previously purchased 6,708,333 founder shares in October 2025 for $25,000. Executive officers receive $15,000 per month in deferred compensation payable upon business combination consummation, alongside a $50,000 monthly administrative services agreement with an affiliate, Valence Management LLC. Why it matters: This filing locks the trust account at exactly $201,250,000 (the filing notes an assumed redemption price of approximately $10.00 per public share), establishing the precise cash floor for future redemptions. It confirms the absolute liquidation deadline of April 16, 2028, with no automatic extension mechanism disclosed beyond board-approved earlier dates. The 80% net trust fair market value target threshold and the alignment of executive pay with successful deal completion are standard SPAC mechanics. Public shareholders retain full redemption rights at trust proportionality (plus interest less taxes), while the Sponsor, officers, and directors have explicitly waived redemption rights on their founder and private shares and contractually pledged to vote any founder shares held in favor of the initial business combination. The registrant states that as of the filing date, it has not selected a specific business combination target and has engaged in no substantive discussions with any prospective target, meaning investor capital remains idle in the trust account awaiting deployment over the remaining ~24 months.

What changed: SEC Form 3 — Initial Statement of Beneficial Ownership. Per the April 22, 2026 filing submitted by Director James Yerbic, zero non-derivative transactions or holdings were reported. This leaves NHIV’s searching status, $10.06 trust/share balance, and April 16, 2028 redemption deadline completely unaltered. No extension votes, redemption window shifts, or sponsor capital adjustments occur. Why it matters: For investors monitoring redemption mechanics and sponsor conduct, the filing establishes a verified baseline of no insider accumulation or reduction. In a SEARCHING vehicle, this negative report eliminates near-term signaling noise regarding deal progression or liquidity pressure, while preserving the existing cash runway and deadline architecture. No claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel accompany the submission.

What changed: Routine compliance exhibit — SEC Form 3 initial ownership report. In its own terms, this document IS a routine compliance exhibit — an SEC Form 3 initial ownership report. Regarding the specified mechanics, the filing records no activity that would adjust the trust value of $10.06 per share, the 2028-04-16 liquidation deadline, any extension timeline, target deal progress, or sponsor conduct. As a further matter of substance, the filing explicitly states that the named reporting person Hammad Samy (President and COO) made no equity-related submissions, noting there are 'No non-derivative transactions or holdings reported.' The document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or additional personnel movements. Why it matters: For investors tracking NHIV’s redemption calendar and search-phase dynamics, this Form 3 establishes a neutral administrative baseline. It does not modify the trust account, shift the redemption deadline, signal enhanced sponsorship alignment, or indicate business combination pursuit. The stated absence of reported holdings reflects standard initial reporting protocol for an insider with no disclosed public equity position, leaving redemption thresholds, extension risk, and capital deployment timelines unchanged.

What changed: Form 3 initial statement of beneficial ownership. Director Charlie Baynes-Reid reported zero non-derivative transactions and no holding adjustments, leaving insider equity exposure completely unchanged. Why it matters: This routine compliance submission confirms no shift in board alignment or derivative-triggering events that could influence sponsor conduct or voting behavior ahead of a proposed merger. The filing contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or additional personnel movements. Consequently, the company’s searching status, per-share trust value, and conversion deadline remain unaltered by this document.

What changed: A Form 3 initial insider ownership report under Section 16(a) of the Securities Exchange Act of 1934, identifying NewHold Investment Corp IV as the issuer and director Scott Scharfman as the reporting person. The filing expressly states “[n]o non-derivative transactions or holdings reported,” confirming that the named director carries no recorded equity positions or derivative contracts at the time of submission. Why it matters: For NHIV investors tracking redemption deadlines, trust valuation, extension triggers, and sponsor conduct, this routine compliance exhibit introduces no alteration to any of those mechanics. The explicit absence of reported insider transactions or balances yields no actionable data regarding management’s confidence in a prospective target, voting posture ahead of the liquidation window, or capital-alignment signals. Outside of standard regulatory disclosures, the document contains zero claims regarding customer metrics, revenue streams, total addressable market, strategic pivots, proprietary technology, commercial partnerships, ongoing litigation, or executive appointments. As a null transaction report, it functions purely as a statutory receipt confirming that no insider equity adjustments triggered SEC disclosure requirements during the reporting period.

What changed: An 8-K Current Report filed by NewHold Investment Corp IV upon the consummation of its initial public offering, detailing the IPO closing, entry into material definitive agreements, unregistered sales of equity securities, and charter amendments. The SPAC completed its IPO of 20,125,000 units at $10.00 per unit, including full exercise of the over-allotment option, generating gross proceeds of $201,250,000. Simultaneously, it completed private placements of 641,250 units (440,000 to Sponsor, 201,250 to BTIG) at $10.00 per unit. Total trust deposit: $201,250,000. The company filed its amended and restated memorandum and articles of association and entered into underwriting, warrant, trust, registration rights, private placement, letter, administrative services, and indemnity agreements. Why it matters: This filing establishes the SPAC's capital structure, trust account ($10.00 per share), and a 24-month deadline to complete a business combination (April 16, 2028). It details sponsor economics, lock-up provisions, and insider commitments to vote for and not redeem shares in a business combination. Investors can now track the trust value, deadlines, and sponsor conduct as the SPAC searches for a target.